Armando Patrizio

Dr. Armando Patrizio

Memorial Sloan Kettering Cancer Center, New York, USA
+1
orcid
Thyroid Cancer Fellow at MSKCC

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Best Practice & Research Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
Alessandro AntonelliAlessandro Antonelli
Alessandro Antonelli
SFSilvia Martina Ferrari
Silvia Martina Ferrari
FRFrancesca Ragusa
Francesca Ragusa
GEGiusy Elia
Giusy Elia
SPSabrina Rosaria Paparo
Sabrina Rosaria Paparo
PFPoupak Fallahi
Poupak Fallahi

Verified
Journal Article
Open access
PDF file
SFSilvia Martina Ferrari
Silvia Martina Ferrari
PFPoupak Fallahi
Poupak Fallahi
MGMaria Rosaria Galdiero
Maria Rosaria Galdiero
IRIlaria Ruffilli
Ilaria Ruffilli
GEGiusy Elia
Giusy Elia
Alessandro AntonelliAlessandro Antonelli
Alessandro Antonelli
A hallmark of cancer is the ability of tumor cells to avoid immune destruction. Activated immune cells in tumor microenvironment (TME) secrete proinflammatory cytokines and chemokines which foster the proliferation of tumor cells. Specific antigens expressed by cancer cells are recognized by the main actors of immune response that are involved in their elimination (immunosurveillance). By the recruitment of immunosuppressive cells, decreasing the tumor immunogenicity, or through other immunosuppressive mechanisms, tumors can impair the host immune cells within the TME and escape their surveillance. Within the TME, cells of the innate (e.g., macrophages, mast cells, neutrophils) and the adaptive (e.g., lymphocytes) immune responses are interconnected with epithelial cancer cells, fibroblasts, and endothelial cells via cytokines, chemokines, and adipocytokines. The molecular pattern of cytokines and chemokines has a key role and could explain the involvement of the immune system in tumor initiation and progression. Thyroid cancer-related inflammation is an important target for diagnostic procedures and novel therapeutic strategies. Anticancer immunotherapy, especially immune checkpoint inhibitors, unleashes the immune system and activates cytotoxic lymphocytes to kill cancer cells. A better knowledge of the molecular and immunological characteristics of TME will allow novel and more effective immunotherapeutic strategies in advanced thyroid cancer.

1 January 2020 in Best Practice & Research Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
Alessandro AntonelliAlessandro Antonelli
Alessandro Antonelli
PFPoupak Fallahi
Poupak Fallahi
GEGiusy Elia
Giusy Elia
FRFrancesca Ragusa
Francesca Ragusa
SPSabrina Rosaria Paparo
Sabrina Rosaria Paparo
SFSilvia Martina Ferrari
Silvia Martina Ferrari

Verified
Journal Article
Open access
PDF file
SFSilvia Martina Ferrari
Silvia Martina Ferrari
PFPoupak Fallahi
Poupak Fallahi
GEGiusy Elia
Giusy Elia
FRFrancesca Ragusa
Francesca Ragusa
IRIlaria Ruffilli
Ilaria Ruffilli
Alessandro AntonelliAlessandro Antonelli
Alessandro Antonelli
Immune checkpoint inhibitors block the checkpoint molecules. Different types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal antibodies (as pembrolizumab and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durmalumab). We collect recent published results about autoimmune endocrine dysfunctions associated with cancer antibody immunotherapies. These agents cause a raised immune response leading to immune-related adverse events (irAEs), varying from mild to fatal, based on the organ system and severity. Immune-related endocrine toxicities are usually irreversible in 50% of cases, and include hypophysitis, thyroid dysfunctions, type 1 diabetes mellitus, and adrenal insufficiency. Anti-PD-1-antibodies are more frequently associated with thyroid dysfunctions (including painless thyroiditis, hypothyroidism, thyrotoxicosis, or thyroid storm), while the most frequent irAE related to anti-CTLA-4-antibodies is hypophysitis. The combination of anti-CTLA-4 and anti-PD-1 antibodies is associated with a 30% chance of irAEs. Symptoms and clinical signs vary depending on the target organ. IrAEs are usually managed by an oncological therapist, but in more challenging circumstances (i.e., for new onset insulin–dependent diabetes, hypoadrenalism, gonadal hormones dysfunctions, or durable hypophysitis) an endocrinologist is needed.

12 October 2021 in Journal of Autoimmunity
Verified
Journal Article
Closed access
APArmando Patrizio
Armando Patrizio
SFSilvia Martina Ferrari
Silvia Martina Ferrari
Alessandro AntonelliAlessandro Antonelli
Alessandro Antonelli
PFPoupak Fallahi
Poupak Fallahi

5 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PFPoupak Fallahi
Poupak Fallahi
GEGiusy Elia
Giusy Elia
RFRagusa Francesca
Ragusa Francesca
SPSabrina Rosaria Paparo
Sabrina Rosaria Paparo
APArmando Patrizio
Armando Patrizio
SFSilvia Martina Ferrari
Silvia Martina Ferrari
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological culprit of COronaVIrus Disease 19 (COVID-19), can enter the cells via the angiotensin-converting enzyme 2 (ACE2) receptor, which has been found in several tissues including in endocrine organs, such as the ovaries, testes, pancreas, and thyroid. Several thyroid disorders have been associated with SARS-CoV-2 infection [subacute thyroiditis (SAT), thyrotoxicosis, and non-thyroidal illness syndrome (NTIS)] and, in part, they are believed to be secondary to the local virus replication within the gland cells. However, as documented for other viruses, SARS-CoV-2 seems to interfere with several aspects of the immune system, inducing the synthesis of autoantibodies and triggering latent or new onset autoimmune disease (AID), including autoimmune thyroid disease (AITD), such as Hashimoto Thyroiditis (HT) and Graves’ disease (GD). Several mechanisms have been hypothesized to explain this induction of autoimmunity by SARS-CoV-2 infection: the immune system hyper-stimulation, the molecular mimicry between the self-antigens of the host and the virus, neutrophils extracellular traps, and finally, the virus induced transcriptional changes in the immune genes; nonetheless, more evidence is needed especially from large, long-term cohort studies involving COVID-19 patients, to establish or reject this pathogenetic relationship.